Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Eli Lilly and Company (NYSE:LLY) showcased strong financial performance in its Q4 2023 Earnings Call, reporting a 20% revenue... Eli Lilly and Company (NYSE:LLY) showcased strong financial ...

In trading on Monday, shares of Eli Lilly (Symbol: LLY) crossed below their 200 day moving average of $855.24, changing hands as low as $839.51 per share. Eli Lilly shares are currently trading ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Investors in Eli Lilly (Symbol: LLY) saw new options become available today, for the October 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced today that Anat Ashkenazi has resigned from her position as Chief... Alphabet (NASDAQ:GOOGL) has appointed Anat Ashkenazi as its new ...